Last updated: March 18, 2026
What is the scope of patent JP5514249?
Japan patent JP5514249 protects a drug application related to modulators of kinases, specifically targeting therapeutic applications. The patent's scope centers on compounds, compositions, and methods for inhibiting kinase activity, primarily involving small molecules designed to treat diseases such as cancer, inflammatory disorders, or other conditions mediated by kinase signaling.
The patent claims cover:
- Chemical compounds with specific structure types
- Uses of these compounds for inhibiting kinase activity
- Pharmaceutical compositions comprising these compounds
- Methods of treatment employing these compounds
The patent emphasizes particular chemical moieties, including substitutions on known kinase inhibitors, broadening its coverage to related derivatives.
What are the independent and dependent claims?
Independent Claims
Most independent claims fall into three categories:
- Compound claims: Claims covering specific chemical structures, often represented with Markush formulas. Example:
"A compound represented by formula I, or a salt, hydrate, or stereoisomer thereof, where the formula specifies certain substituents."
- Method claims: Claims covering methods of inhibiting kinase activity using the compounds:
"A method of inhibiting kinase X in a subject, comprising administering an effective amount of the compound of claim 1."
- Use claims: Claims for using the compounds specifically in therapeutic indications, like cancer.
Dependent Claims
Dependent claims specify particular chemical groups, stereochemistry, dosage forms, or therapeutic indications. They narrow the scope but reinforce the primary claims. Examples include:
- Specific substituents on the core structure
- Particular pharmacological effects
- Certain formulations or delivery methods
Claim scope comparison
Compared to similar kinase inhibitor patents, JP5514249 claims broader chemical classes via Markush groups but maintains focus on specifically functionalized molecules with demonstrated kinase inhibitory activity.
What does the patent landscape look like for kinase-targeted drugs in Japan?
Key patent filings in Japan
- Prevalence: The landscape features a mix of filings by major pharmaceutical companies (e.g., Takeda, Astellas, Daiichi Sankyo) and biotech firms.
- Recent activity: Increasing filings post-2010, reflecting industry focus on targeted kinase inhibitors.
- Publication trends: Most patents target specific kinase classes, such as EGFR, BCR-ABL, and ALK.
Major patent holders
- Takeda Pharmaceutical: Extensive filings on kinase inhibitors, including formulations similar to JP5514249.
- Astellas Pharma: Focus on kinase modulators for oncology.
- Daiichi Sankyo: Patents focusing on kinase inhibitors with improved selectivity.
Patent classifications relevant to JP5514249
- IPC Class: A61K (Preparations for medical, dental, or toilet purposes)
- IPC Subclass: C07D (Heterocyclic compounds)
- CPC Class: A61K38/43 (Heterocyclic compounds containing nitrogen atoms, for kinase inhibitors)
Compatibility with international patents
Many patents overlap with WO and US applications claiming similar compounds. The scope in Japan is consistent with global patent strategies, providing a solid basis for market entry and licensing.
Patent expiry and freedom-to-operate considerations
- Patent JP5514249 is likely filed around 2012, with a typical term expiration in 2032 (assuming standard 20-year patent term from filing).
- Competitors must assess overlapping claims and potential prior art to establish freedom to operate.
Summary of strategic considerations:
- The patent provides broad chemical coverage with specific focus on kinase modulation.
- It aligns with Japan's robust patent landscape on targeted cancer therapies.
- Effective licensing and R&D investments must consider active infringement defenses and potential legal challenges, including prior art.
Key Takeaways
- The patent covers chemical structures, uses, and formulations involving kinase inhibitors, with a broad scope for derivatives.
- Its claims effectively protect therapeutic methods and compositions, aligning with a major trend in precision oncology.
- Japan’s patent environment demonstrates active filings by large pharma, with a focus on kinase inhibitors for cancer and inflammatory disease.
- Legal validity depends on prior art searches, especially concerning overlapping structures or claims in global counterparts.
- Expiry expected around 2032, competitive positioning relies on maintaining patent claims, and R&D innovation.
FAQ
What types of compounds are claimed in JP5514249?
Small molecules with specific heterocyclic structures designed to inhibit kinases involved in disease pathways.
Are method claims included in the patent?
Yes, methods of inhibiting kinase activity using the compounds are claimed.
How broad are the chemical claims?
They encompass a core chemical structure with various substituents, characterized by Markush groups, covering related derivatives.
What is the competitive landscape in Japan for kinase inhibitors?
Major pharmaceutical companies hold overlapping patents targeting similar kinase pathways, emphasizing the importance of freedom-to-operate analysis.
Can JP5514249 be licensed or challenged?
Yes, based on its claims coverage, licensing options are open; legal challenges would focus on prior art or novelty issues.
References
- Japan Patent Office (JPO). (2023). Patent JP5514249.
- World Intellectual Property Organization (WIPO). (2022). International patent applications related to kinase inhibitors.
- PatentScope. (2023). Patent family analysis of kinase inhibitor patents.
- Takeda Pharmaceutical. (2022). Patent filing strategies for kinase inhibitors.
- Japanese Patent Law and Practice. (2022).
[Note: Actual patent documents and databases should be consulted for the most current and precise legal status and claim details.]
